Author(s):
M.E. Kannan, Debjani Singh, Yogesh Wagh, Dinesh Patel, Bhavesh Patel, Devendra Badgujar, Tushar Nahata
Email(s):
tusharnahata@zyduslife.com
DOI:
10.52711/0974-360X.2026.00321
Address:
M.E. Kannan, Debjani Singh, Yogesh Wagh, Dinesh Patel, Bhavesh Patel, Devendra Badgujar, Tushar Nahata*
Pharmaceutical Technology Center, Zydus Lifesciences Limited, Ahmedabad, Gujarat, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Multidose parenteral products administered using reusable injection devices require a scientifically justified in-use period due to repeated breaches of container closure integrity during use. Innovative Semaglutide injection 15 mg/3 mL (5 mg/mL) is a preserved multidose formulation supplied in a reusable pen system. An in-use stability study was conducted to understand the in-use storage stability. Prefilled cartridges were assembled into the reusable pen device were subjected to worst-case simulated use involving up to 32 needle punctures and stored for up to 8 months at 2–8 °C and 56 days at 15–30 °C. Samples were evaluated at predefined intervals for physicochemical quality attributes, preservative content, particulate matter, and antimicrobial effectiveness in accordance with applicable compendial requirements and predefined acceptance criteria. All tested parameters remained within specifications throughout the study, with no clinically relevant trends observed. The generated data confirmed the in-use storage stability of semaglutide multidose formulation.
Cite this article:
M.E. Kannan, Debjani Singh, Yogesh Wagh, Dinesh Patel, Bhavesh Patel, Devendra Badgujar, Tushar Nahata. In-use Stability of Semaglutide Injection 15mg/3mL (5mg/mL) In-use Storage Conditions, Study Design, Study Outcome and Labelling Recommendations. Research Journal Pharmacy and Technology. 2026;19(5):2229-5. doi: 10.52711/0974-360X.2026.00321
Cite(Electronic):
M.E. Kannan, Debjani Singh, Yogesh Wagh, Dinesh Patel, Bhavesh Patel, Devendra Badgujar, Tushar Nahata. In-use Stability of Semaglutide Injection 15mg/3mL (5mg/mL) In-use Storage Conditions, Study Design, Study Outcome and Labelling Recommendations. Research Journal Pharmacy and Technology. 2026;19(5):2229-5. doi: 10.52711/0974-360X.2026.00321 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-42
REFERENCES:
1. United States Pharmacopeia–National Formulary (USP–NF) Antimicrobial Effectiveness Testing ⟨51⟩; United States Pharmacopeial Convention: Rockville, MD, 2026.
2. Indian Pharmacopoeia Commission Effectiveness of Antimicrobial Preservatives (IP 2.2.2); Indian Pharmacopoeia Commission: Ghaziabad, India, 2026.
3. United States Pharmacopeia–National Formulary (USP–NF) Particulate Matter in Injections ⟨788⟩; United States Pharmacopeial Convention: Rockville, MD, 2026.
4. United States Pharmacopeia–National Formulary (USP–NF) Visible Particulate in Injections ⟨790⟩; United States Pharmacopeial Convention: Rockville, MD, 2026.
5. Indian Pharmacopoeia Commission Particulate Contamination (IP 2.5.9); Indian Pharmacopoeia Commission: Ghaziabad, India, 2026.
6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) ICH Q1A(R2): Stability Testing of New Drug Substances and Products; ICH: Geneva, Switzerland, 2003.